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CLINICAL REPORT
Acta Derm Venereol 2007; 87: 406–412
Atopic dermatitis often requires long-term treatment. 
This European, multicentre, non-comparative, 24-month, 
follow-up study investigated the efficacy and safety of 
0.1% tacrolimus ointment applied to adults with atopic 
dermatitis. Patients (n = 672) applied a thin layer of 
0.1% tacrolimus ointment twice daily for 3 weeks to all 
affected body areas. After 3 weeks, ointment was applied 
once daily. Clinical improvement became apparent after 
2 weeks of treatment and 65.5% of patients had a rating of 
clearance, excellent or marked improvement by month 3. 
Skin burning (31.7%) was the most common causally-
 related adverse event, followed by pruritus (11.3%) 
folliculitis (6.4%), alcohol intolerance (5.7%), herpes 
simplex (5.7%), skin infection (4.6%), skin erythema 
(3.3%) and hyperaesthesia (2.4%). The most commonly 
reported infections were flu syndrome (12.9%), skin 
infection (9.8%), folliculitis (7.4%) and herpes simplex 
(7.0%). Long-term treatment up to 24 months with 0.1% 
tacrolimus ointment is safe and efficacious in adults with 
atopic dermatitis. Key words: atopic dermatitis; long-term 
treatment; tacrolimus ointment.
(Accepted February 14, 2007.)
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Atopic dermatitis (AD) tends to be a chronic disease with 
a relapsing course. Long-term treatment is usually neces-
sary to control and prevent flares, and patients require 
medication that is safe and efficacious when applied 
continuously or intermittently over a prolonged period 
of time. Tacrolimus ointment was developed specifically 
for the treatment of AD, and the twice daily application 
of 0.1% tacrolimus ointment has proven to be effective 
in improving the clinical condition of adults with mode-
rate to severe AD (1–3). However following reports of 
lymphoma and skin cancer in children and adults app-
lying topical calcineurin inhibitors, such as tacrolimus 
and pimecrolimus, in April 2005 the European Agency 
for the Evaluation of Medicinal Products (EMEA) started 
a safety review of tacrolimus and pimecrolimus in the 
treatment of AD (4).
The main concern of the health authorities is not that 
topical calcineurin inhibitors have a direct carcinogenic 
effect, but rather that they cause systemic immunosup-
pression, thus enabling the progression of malignancy. 
Studies investigating the systemic absorption of tacroli-
mus ointment have reported that absorption is minimal 
in most patients and there is no evidence of cumulative 
immunosuppression (5, 6). High blood levels of tacro-
limus have been observed only in patients who have a 
severely impaired epidermal barrier (7) and tacrolimus 
ointment is contra-indicated for such patients. 
The effect of topical calcineurin inhibitors on the im-
mune system has been investigated in vaccination studies. 
The seropositivity rates for tetanus, diphtheria, measles or 
rubella in children with AD following vaccination were 
found to be unaffected after 2 years of treatment with 
1% pimecrolimus cream (8). In addition, it was shown 
recently that 0.03% tacrolimus ointment had no effect on 
the immediate response to vaccination, the generation of 
immune memory, or humoral and cell-mediated immu-
nity in children with moderate to severe AD vaccinated 
against meningococcal serogroup C (9). Investigating 
the outcome of long-term treatment with calcineurin 
inhibitors, Koo et al. (10) treated 7923 patients for up 
to 23 months with 0.03% or 0.1% tacrolimus ointment 
and found no increase in the incidence of infections or 
other adverse events. In an open-label study, Hanifin et 
al. (11) followed up 300 patients who applied 0.1% tacro-
limus ointment either continuously or intermittently for 
4 years. The authors noted no increase in the incidence 
of cutaneous infections with long-term treatment, and 
the incidence rates of varicella zoster (chicken pox and 
shingles) and flu-like symptoms were comparable with 
the expected rates in the general population. 
A definite link between topical calcineurin inhibitors 
and cancer has not been established. In March 2006, 
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the EMEA concluded, following its review, that the 
benefits of using tacrolimus and pimecrolimus outweigh 
the risks, but more long-term safety data are required 
accurately to assess any risk to patients using these 
treatments. Here we report the first long-term data 
from a European multicentre, open-label, follow-up 
study that investigated the efficacy and safety of 0.1% 
tacrolimus ointment applied for up to 24 months to 
adults with AD. 
METHoDS
Study design
This was a 24-month, multicentre, non-comparative, phase 
III/IV, follow-up study conducted in 52 centres in 12 European 
countries. All study centres that had previously contributed to 
the 6-month comparative study, i.e. 0.1% tacrolimus ointment 
vs. corticosteroid ointment regimen (1) were invited to partici-
pate. The study was conducted in accordance with the ethical 
principles described in the Declaration of Helsinki, and the 
Ethics Committee of each centre reviewed the protocol and 
granted approval before the start of the study. Patients were 
to remain in the study until the next scheduled visit following 
product launch. Assessments were performed on day 1, week 
2, month 1, month 3 and 3-monthly thereafter. 
Patients
Following written informed consent from the patient, male and 
female patients aged 18 years or older with a diagnosis of AD based 
on the criteria of Hanifin & Rajka (12) were enrolled in the study. 
Method of assigning patients to the treatment group
A unique number was allocated to each patient as he or she 
entered the follow-up study. A gap of at least 3 days was en-
sured between the last application of study medication in the 
6-month study and the first application of 0.1% tacrolimus 
ointment in this study. 
Treatment
Patients applied a thin layer of 0.1% tacrolimus ointment twice 
daily for 3 weeks to all affected body areas. Up to 100% of 
the body surface area (BSA) could be treated until the lesions 
cleared (i.e. stopped itching). After 3 weeks, the patients applied 
tacrolimus ointment once daily until clearance. Patients were 
required to mark in their diary whether ointment was applied 
each day and, if so, whether one or two applications were made. 
In the event of flare or a worsening of the clinical condition, 
twice daily ointment application resumed for another 3 weeks 
and the change in application regimen was recorded in the 
patient diary. All of the used and unused ointment tubes for 
each patient were weighed at the end of the study so that total 
ointment usage could be calculated.
Therapies that were prohibited during the study included 
topical corticosteroids for the treatment of AD, systemic corti-
costeroids, ultraviolet radiation treatments, and systemic non-
steroidal immunosuppressive agents. The wash-out phase for 
these therapies ranged from a minimum of 3 days (for topical 
corticosteroids and systemic corticosteroids) to a maximum of 
6 weeks (for ultraviolet (UV) treatments) prior to the start of 
the study. The wash-out period for systemic non-steroidal im-
munosuppressants was 2 weeks. Patients were allowed to use 
a non-medicated emollient 2 hours before and after tacrolimus 
ointment application. 
Assessments
Efficacy end-points included the physician’s global evaluation 
of clinical response, physician’s evaluation of clinical response 
on head and neck, physician’s assessment of individual signs, 
affected area assessment, patient’s assessment of global re-
sponse, patient’s assessment of global response for head and 
neck, and the Eczema Area and Severity Index (EASI; 13). Full 
details of these assessments are described in the 6-month study 
publication (1). Patient quality of life was measured using the di-
sease-specific Dermatology Life Quality Index (DLQI). Safety 
assessments during the study included the monitoring of adverse 
events and vital signs, as well as clinical laboratory evaluations 
(haematology and clinical chemistry, including measurements of 
hepatic and renal function). An adverse event was defined as any 
untoward occurrence in a patient during the study, regardless 
of whether it was related to the study treatment. 
Statistical methodology
The sample size for this study was not based on statistical 
assumptions. As this study was a follow-up of the 6-month 
study, the sample size was limited by the number of patients 
who participated in the original study. The duration of the study 
varied among patients and, for this reason, the last observation 
carried forward LoCF rule was applied for month 6, month 12, 
month 18, month 24 and end of study visits. The intent-to-treat 
population was used for all of the analyses and included all 
patients who received at least one application of study ointment. 
No statistical tests were performed.
RESULTS
Patient demographics and baseline data
In total, 672 patients formed the intent-to-treat popula-
tion. Patient demographics and baseline characteristics 
of the study population are shown in Table I. 
Patient disposition
A total of 185 patients (27.5%) discontinued the study, 
the most common reason for discontinuation being lack 
of efficacy (71 patients, 10.6%). Lost to follow-up (45, 
6.7%), withdrawal of consent (23, 3.4%), adverse event 
(17, 2.5%) and non-compliance (14, 2.1%) were also 
reasons for study discontinuation. Except for the UK, 
where the patients participated in the study for a fixed 
period of 6 months, the patients remained in the study 
until the next scheduled visit following product launch 
in the respective country. Consequently, the majority 
of patients (338, 69.5%) completed the study between 
months 4 and 12, while 114 patients (23.4%) continued 
to apply ointment between months 13 and 24. 
Ointment usage
of the 640 patients who returned their diaries, 619 
applied tacrolimus ointment once daily at least once 
during the study, while 624 patients applied ointment 
twice daily at least once during the study. The overall 
median percentage of treatment days was 69.9% of 
the study duration when taking into account days with 
missing information as non-treatment days, and 83.6% 
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when considering days with missing information as 
treatment days. The median number of treatment epi-
sodes per patient was 1.0 and the median duration of 
treatment episodes was 45 days (Table II). 
The median tacrolimus ointment use per day between 
day 1 and month 3 was 1.2 g, decreasing to 0.7 g between 
months 10–12, and 0.5 g by months 22–24. Total median 
ointment used during the entire study was 1.0 g/day.
Efficacy outcomes
Clinical improvement was observed after 2 weeks of 
treatment and the results for EASI and affected body 
surface area showed that most patients experienced 
considerable improvement in the signs and symptoms 
of their AD. Median EASI decreased from 8.4 on day 1 
to 0.4 by month 24, while the median percentage affec-
ted total BSA decreased from 16.0 to 1.5, respectively 
(Figs. 1 and 2). The ratings of the physician’s global 
evaluation of clinical response reflected the clinical 
improvement as measured by EASI, with 30.4% of 
patients receiving a rating of cleared or excellent im-
provement at week 2 and 43.8% of patients by month 3 
(Table III). Patients were also extremely satisfied with 
their improvement and at week 2, 70.5% of patients as-
sessed their overall response as much better or better. 
Separate analyses of the head and neck area showed 
overall results similar to the analyses of combined 
body regions: 37.3% of the patients received a rating 
of cleared or excellent after 2 weeks of treatment, while 
73.9% of the patients assessed their head/neck area to 
be much better or better. Patients reported a progressive 
improvement in quality of life throughout the study. At 
the day 1 visit, the median DLQI was 6.0, and decreased 
to 3.0 by month 3 and 1.5 by month 24. 
Safety outcomes
A total of 366 patients (54.5%) experienced adverse 
events that were assessed by the study investigators 
to be related to the study ointment. Skin burning (213 
patients, 31.7%) and pruritus (76, 11.3%) were the most 
common causally-related adverse events and occurred 




Mean ± SD 33.5 ± 11.8
Median (min–max) 31 (18–85)
Male: female, n (%) 329 (49.0): 343 (51.0)










Total affected BSAb, day 1
  Mean±SD
  Median (min–max)
23.5±22.0
16.0 (0–99.5)
Total affected BSA, day 1, n (%)
0 to ≤25% 441 (65.6)
>25% to ≤50% 136 (20.2)
>50% to ≤75% 69 (10.3)
>75% to ≤100% 26 (3.9)
Affected body region (day 1), n (%) 
Head and neck 580 (86.3)
Upper limbs 636 (94.6)
Trunk 524 (78.0)
Lower limbs 512 (76.2)
Percentage affected BSA, (day 1) Median (min–max)
Head and neck 25 (0–100)
Upper limbs 20 (0–100)
Trunk 15 (0–100)
Lower limbs 10 (0–100)
aIntent-to-treat population. 
bAffected BSA as a percentage of total BSA.
SD: standard deviation; AD: atopic dermatitis; BSA: body surface area.
Table II. Number and duration of treatment episodesa 
0.1% tacrolimus (n = 672)b
Assuming days with missing 
information as 
Not treated Treated
No. of treatment episodesc/patient
Number of patients 640 640
Mean±SD 1.7±1.3 1.8±1.3
Median (min–max), n (%) 1 (0–8) 1 (0–8)
Duration of treatment episodes (days)
Total number of episodes 1114 1147
Mean±SD 85.5±104.1 97.2±115.5
Median (min–max), n (%) 45 (7–799) 51 (7–799)
aBased on diary data, excluding 32 patients who did not return their 
diaries. An episode is defined as at least 7 days of treatment in a row. 
If in the following 3 weeks (after the last 7-day treatment period) there 
are another at least 7 days of consecutive treatment, then the episode is 
extended to the last day of that subsequent treatment period.
bIntent-to-treat population. SD: standard deviation.
cone patient may have more than one treatment episode.
Fig. 1. Median Eczema Area and Severity Index (EASI) between visit at day 
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most often at the site of ointment application (Table 
IV). In 80% of patients, skin burning and pruritus 
were assessed as being mild to moderate in severity, 
and after 2 weeks of treatment, the prevalence of 
both side-effects decreased greatly. of the 17 patients 
(2.5%) applying tacrolimus ointment who discontinued 
the study because of adverse events, skin burning (8 
patients) was the most common reason for premature 
study discontinuation. other adverse events leading 
to study discontinuation included herpes simplex (2 
patients), folliculitis, pruritus, eczema, skin infection, 
manic depressive reaction, application-site reaction and 
hypertension (all 1 patient, respectively). 
Few serious adverse events occurred during the study 
(28 patients, 4.2%). The most commonly reported serious 
adverse event was lack of drug effect (7, 1.0%) followed 
by accidental injury (4, 0.6%). Four patients (0.6%) 
experienced a serious adverse event that was assessed 
as being related to treatment: one patient with severe 
eczema herpeticum at the sites of ointment application 
on the head/neck and upper limbs on day 228, one patient 
with severe erythrodermic eczema at both treated and 
untreated sites all over the body on day 29, and 2 patients 
with exacerbation of AD (days 61 and 78). Tacrolimus 
ointment application was discontinued in all 4 patients.
Reports of infections, benign neoplasms and malig-
nancies were examined carefully. The most commonly 
reported infections during this study were flu syndrome 
(12.9%), skin infection (9.8%), folliculitis (7.4%) and 
herpes simplex (7.0%; Table V). With regard to herpes 
simplex, except for 6 patients (0.9%) who had severe 
herpes simplex that required medical intervention, all 
other cases of herpes simplex were mild to moderate in 
severity. In addition, the prevalence of herpes simplex 
decreased throughout the study period in parallel with 
the decrease in severity and extent of disease as the skin 
barrier function improved (Fig. 3). Two malignancies 
were reported during the study, and in both patients 
the relationship to tacrolimus ointment was assessed 
as being unlikely. Bowen’s disease was diagnosed in a 
58-year-old man on day 245, (the patient continued with 
the study ointment and recovered) and a prostate cancer 
was identified in an 82-year-old patient on day 119. 
With respect to the 7 patients with benign skin 
neoplasms, 5 had neoplasms that were assessed by the 
physician as having an unlikely relationship to the study 
ointment (each one patient: seborrhoeic wart, strange 
coloured mole, junctional nevus, molluscum pendulum, 
inflammatory sebaceous cyst). Two patients had benign 
skin neoplasms that were possibly related to the study 
medication (one patient with a wart and one patient with 
neck skin tags). All 7 patients continued with tacrolimus 
ointment application and recovered prior to the end of 
the study.
Twenty-seven patients had at least one laboratory 





























Fig. 2. Median percentage affected total body surface area (BSA) between 
visit at day 1 and month 24. LoCF: Last observation Carried Forward.
Table III. Clinical improvement in atopic dermatitis between day 




Physician’s Global Evaluation of Clinical Response
Cleared or excellent improvement
Week 2
Month 3 








Cleared or excellent improvement
Week 2
Month 3 







Patient’s Assessment of Global Response
Much better or better
Week 2
Month 3 








Much better or better
Week 2
Month 3 








LoCF: Last observation Carried Forward; N: total number of patients.
Table IV. Incidence of most commona causally related adverse 
events during 0.1% tacrolimus therapy (n=672)b
CoSTARTc term n (%)
Skin burning 213 (31.7)
Pruritus 76 (11.3)
Folliculitis 43 (6.4)
Alcohol intolerance 38 (5.7)
Herpes simplex 38 (5.7)
Skin infection 31 (4.6)
Lack of drug effect 22 (3.3)
Skin erythema 22 (3.3)
aAt least 2% of patients.
bIntent-to-treat population. 
cFood and Drug Administration’s (FDA) Coding Symbols for a Thesaurus 
of Adverse Reaction Terms (CoSTART).
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to be clinically relevant by the investigator. None of 
these clinically-relevant laboratory values affected the 
management of the patient or led to discontinuation of 
the patient from the study. 
DISCUSSIoN
This is the first European study to investigate the long-
term efficacy and safety of 0.1% tacrolimus ointment 
applied either continuously or intermittently for up to 
24 months to adults with AD. The efficacy data showed 
clearly that the patients had substantial improvement 
in the signs and symptoms of AD. Large decreases in 
total affected BSA and EASI became apparent after 2 
weeks of treatment and clinical improvement conti-
nued throughout the study. The positive results of the 
DLQI showed that patients had a greater feeling of 
well-being and felt that their lives were less impaired 
by their disease. Treatment efficacy was maintained in 
the majority of patients who required only one to two 
treatment episodes during the study period, and the total 
amount of ointment applied decreased as the condition 
of the skin improved. This is of particular importance 
as there is concern that patients who have large affected 
areas and open lesions may be at a risk of increasing 
their systemic exposure to tacrolimus. Rubins et al. (6) 
found that in 32 adults with moderate to severe AD, 
96% of the blood samples assayed contained tacrolimus 
concentrations below 1 ng/ml and 23% of the samples 
were below the lower limit of quantification (0.025 
ng/ml. As treatment with tacrolimus ointment normally 
helps to restore the skin barrier quickly, exposure to 
tacrolimus is reduced as the lesions heal. In a 12-
month, open-label study in 316 patients with moderate 
to severe AD, tacrolimus whole blood concentrations 
decreased from 0.32 ng/ml at week 1 to 0.13 ng/ml at 
month 12 (14). Nonetheless, patients should be moni-
tored carefully to identify any side-effects related to 
long-term treatment, and additional studies measuring 
whole blood concentrations of tacrolimus in patients 
applying tacrolimus ointment for prolonged periods of 
time will help clarify whether systemic accumulation 
can occur with long-term treatment. 
Irritation at the site of ointment application is the 
most common adverse effect associated with tacrolimus 
ointment and has been reported in both short-term and 
long-term clinical studies (15). Transient skin burning 
at the site of ointment application was the most common 
adverse event reported during our study, and in most 
patients, was mild to moderate in severity, decreased in 
prevalence after the first 2 weeks of treatment, and only 
a few patients required medical intervention. As there 
is concern that the prolonged application of tacrolimus 
ointment may cause systemic immunosuppression, we 
investigated infections and malignancies in detail. The 
nature and incidence of infections observed during the 
study were consistent with what has been reported pre-
viously in a cohort of patients with AD followed for this 
length of time (11). With regard to cutaneous infections, 
the overall incidence of herpes simplex in the patients in 
our study was 7%, which is in agreement with reported 
incidence rates in patients with AD of 6–10% (16, 17). 
only one patient (0.1%) developed eczema herpeticum, 
which is a very low incidence compared with previous 
reports (18). our data are in agreement with those of 
Fleischer et al. (19) who analysed the data for 1554 
patients with AD treated with tacrolimus ointment in 
five clinical trials for time periods ranging between 12 
weeks and up to 12 months. They found that the risk 
of cutaneous bacterial, viral, or fungal infections did 
not increase with long-term treatment. Importantly in 
our study, the prevalence of herpes simplex decreased 
over time despite patients with AD often having a high 
risk of recurrent herpes simplex infections (20), and it 
is possible that the clinical efficacy of tacrolimus oint-
ment in improving the epidermal barrier may decrease 
the risk of local infection. 
We observed only 2 malignancies (Bowens disease 
and prostate cancer) that occurred during the study, 
Table V. Overall incidence of most commona infections and incidence 
of all benign neoplasms and malignancies, irrespective of causality, 
during 0.1% tacrolimus therapy (n=672)b
CoSTARTc term n (%)
Infections
Flu syndrome 87 (12.9)
Skin infection 66 (9.8)
Folliculitis 50 (7.4)





Skin neoplasm benign 7 (1.0)
Prostatic carcinoma 1 (0.1)
Skin cancer 1 (0.1)
aAt least 2% of patients.
bIntent-to-treat population.
cFood and Drug Administration’s (FDA) Coding Symbols for a Thesaurus 
of Adverse Reaction Terms (CoSTART).
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both of which were considered to be unrelated to the 
study ointment. In other clinical studies of tacrolimus 
ointment, there has been no evidence of an increased 
risk of lymphoma, lymphoproliferative disorders, or skin 
cancers associated with the use of tacrolimus ointment 
(14, 22). The overall rate of lymphoma in the US general 
population is 22/100 000 person years and it has been re-
ported that the overall rate in tacrolimus-treated patients 
is 0.65/100 000 (23). With regard to skin cancer, Naylor 
et al. (24) studied the data of 9813 adult and pediatric 
patients with moderate to severe AD who applied 0.03% 
or 0.1% tacrolimus ointment twice daily. The patients 
were evaluated every 3 months, with the mean duration 
of observation being 208 days and the longest period of 
observation 1479 days. Thirteen patients of 4761 adult 
patients with AD (0.27%) were diagnosed with unrelated 
non-melanoma skin cancer, and the authors concluded 
that there was no increased risk of non-melanoma skin 
cancer in patients applying tacrolimus ointment compa-
red with the general US population. 
Topical calcineurin inhibitors have only been av-
ailable for the last 5–6 years, but already there have 
been more than 5.4 million prescriptions of tacrolimus 
ointment worldwide (23). Although more information is 
required regarding long-term outcome with tacrolimus 
ointment, the long-term safety data currently available 
are encouraging. The results of this 24-month study con-
firm that the application of 0.1% tacrolimus ointment, 
either continuously or intermittently, is efficacious in 
reducing the signs and symptoms of AD in adults, and 
that treatment efficacy can be maintained successfully. 
The safety profile observed in our patients is consistent 
with previous reports, and no increase in infection, 
malignancy, or other cumulative side-effects were no-
ted following the prolonged application of tacrolimus 
ointment. In conclusion, tacrolimus ointment has an 
invaluable role in the challenging management of AD, 
and additional long-term, follow-up studies will help 
to address and further elucidate the safety profile of 
long-term tacrolimus ointment treatment.
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